

Flu-Baan[®]

Osetamivir Phosphate

Care to Cure



Flu-Baan[®]

Oseltamivir Phosphate

Flu-baan[®] is a prescription antiviral medication that can be used to treat an influenza infection (also known as the flu) in children and adults if their symptoms have started within the last day or two. It can also be used to prevent the flu in children, teens, and adults who have been exposed to the influenza virus.

Medicinal product

Flu-baan[®] 30 / 75 mg capsules

Pharmacologic Category

Antiviral Agent; Neuraminidase Inhibitor

Therapeutic indications

Influenza, seasonal, prophylaxis: Prophylaxis of influenza (A or B) infection in patients ≥ 1 year of age.

Influenza, seasonal, treatment: Treatment of uncomplicated acute illness due to influenza (A or B) infection in patients ≥ 2 weeks of age who have been symptomatic for no more than 48 hours.

Off-label: Influenza A, avian (H7N9 or H5N1), prophylaxis; Influenza A, avian (H7N9 or H5N1), treatment

Dosing adults

	Prophylaxis		treatment
	Preexposure	Postexposure	
Seasonal Influenza	75 mg once daily during influenza activity or for 2 weeks following vaccination	75 mg once daily for 1 week (if vaccinated) 75 mg once daily for 2 weeks (if unvaccinated)	75 mg twice daily for 5 days a longer duration can be considered in severely ill or immunocompromised patients.
Influenza A, avian (Off-label use)	75 mg twice daily for 5 days		75 mg twice daily for 5 days

Dosing pediatrics

		Influenza, treatment	Influenza, prophylaxis
Infants 3 to 8 months		3 mg/kg/dose twice daily	3 mg/kg/dose once daily
Infants ≥ 9 months		3.5 mg/kg/dose twice daily	3.5 mg/kg/dose once daily
Children	≤ 15 kg	30 mg twice daily	30 mg once daily
	>15 kg to 23 kg	45 mg twice daily	45 mg once daily
	>23 kg to 40 kg	60 mg twice daily	60 mg once daily
	>40 kg: Oral	75 mg twice daily	75 mg once daily

Mechanism of action

Oseltamivir, a prodrug, is hydrolyzed to the active form, oseltamivir carboxylate (OC). OC inhibits influenza virus neuraminidase, an enzyme known to cleave the budding viral progeny from its cellular envelope attachment point (neuraminic acid) just prior to release.

Contraindication

Hypersensitivity to oseltamivir or any component of the formulation

Special warnings and precautions for use

Flu-baan® is not a substitute for influenza vaccination

- Severe concomitant condition
- Immunocompromised patients
- Cardiac/respiratory disease
- Severe renal impairment
- Neuropsychiatric events

Pregnancy and breastfeeding


US FDA pregnancy category: C

According to the US CDC, this drug is preferred for the treatment of pregnant women with suspected/confirmed influenza.

Breastfeeding: Caution is recommended; benefits should outweigh risks.

Benefits and efficacy

- oseltamivir significantly reduced the duration of influenza and lowered the risk of developing otitis media³



- reduce influenza illness duration and virus shedding⁴
- administration of oseltamivir was associated with shorter length of hospital stay and earlier recovery and discharge of the hospital, and a lower mortality rate⁵

References

- www.uptodate.com
- www.drugs.com
- Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials | Clinical Infectious Diseases | Oxford Academic (oup.com)
- Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial - PubMed (nih.gov)
- Efficacy of oseltamivir in the treatment of patients infected with Covid-19 - PubMed (nih.gov)



+98 (21) 44504841
www.tehrandarou.com
tehrandarou
+98 9358933828
9th. Km of Karaj Makhsoos Rd. Tehran-IRAN,
Tehran Darou Pharmaceutical Company

